What type of study is this?

This is a Animal Study study (also classified as: Pre-Registered Trial).

What question did this study set out to answer?

The study aims to assess BRAFV600E persistence and immune cell distribution under MEKi in histiocytosis patients.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Research shows incomplete clearance of BRAFV600E in LCH and ECD blood, indicating need for combined therapies.

The study aims to assess BRAFV600E persistence and immune cell distribution under MEKi in histiocytosis patients.
Analyzed 181 blood and bone marrow samples from 149 patients with histiocytosis.
Quantified BRAFV600E variant allele frequency using droplet digital PCR.
Utilized murine model treated with trametinib to evaluate drug effects on mutated cells.
BRAFV600E persisted in bone marrow progenitors with no significant reduction under MEKi.
Immunohistochemistry showed reduced mutated cells in spleen, but not in brain or liver.
B cells emerged as a new reservoir for BRAFV600E during MEKi therapy.

Ungureanu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark